F. Nowak

发表

Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial

J. Blay, I. Bièche, G. Ferretti, 2016 .

Europe does it better: molecular testing across a national health care system-the French example.

J. Soria, F. Calvo, F. Nowak, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping

J. Sabourin, F. Nowak, N. Piton, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience

G. Chatellier, P. Laurent-Puig, I. Durand-zaleski, 2013, PloS one.

Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.

B. Tops, P. Laurent-Puig, I. Soubeyran, 2016, The Journal of molecular diagnostics : JMD.

IPM‐FISH, a new M‐FISH approach using IRS‐PCR painting probes: Application to the analysis of seven human prostate cell lines

A. Vannier, F. Nowak, J. Aurich-Costa, 2001, Genes, chromosomes & cancer.

Tumour molecular profiling for deciding therapy—the French initiative

J. Soria, F. Calvo, F. Nowak, 2012, Nature Reviews Clinical Oncology.

Equal access to innovative therapies and precision cancer care

J. Blay, G. Vassal, D. Pérol, 2016, Nature Reviews Clinical Oncology.

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests

D. Khayat, R. Lidereau, M. Picot, 2013, Breast Cancer Research and Treatment.

Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups

F. André, P. Viens, L. Lacroix, 2012, Clinical Cancer Research.

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

P. Laurent-Puig, J. Sabourin, J. Emile, 2013, BMC Cancer.

Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

J. Mosser, F. Penault-Llorca, J. Soria, 2013 .

[Cancer genetics: estimation of the needs of the population in France for the next ten years].

J. Saurin, C. Bonaïti‐pellié, D. Stoppa-Lyonnet, 2009, Bulletin du cancer.

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience

G. Chatellier, P. Laurent-Puig, I. Durand-zaleski, 2013, PloS one.

Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.

B. Tops, P. Laurent-Puig, I. Soubeyran, 2016, The Journal of molecular diagnostics : JMD.